| 항목 |
내용 |
| DUR (의약품사용평가) |
병용금기 :
고시된 병용금기 내용은 없습니다.
[상호작용/병용금기검색]
연령대금기 :
고시된 연령금기 내용은 없습니다.
[연령대금기상세검색]
|
| 독성정보 |
Bacitracin에 대한 독성정보 : 정보보기
출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Bacitracin에 대한 Mechanism_Of_Action 정보
Bacitracin intereferes with the dephosphorylation of the 55-carbon, biphosphate lipid transport molecule, which carries the building blocks of the peptidoglycan bacterial cell wall outside the inner membrane for construction.
zinc에 대한 Mechanism_Of_Action 정보
Not Available
Neomycin에 대한 Mechanism_Of_Action 정보
Aminoglycosides like neomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically neomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
|
| Pharmacology |
Bacitracin에 대한 Pharmacology 정보
Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. As a polypeptide, toxic, and difficult to use chemical, Bacitracin doesn't work well orally, however is very effective topically. Bacitracin exerts pronounced antibacterial action in vitro against a variety of gram-positive and a few gram-negative organisms. However, among systemic diseases, only staphylococcal infections qualify for consideration of bacitracin therapy.
zinc에 대한 Pharmacology 정보
Not Available
Neomycin에 대한 Pharmacology 정보
Neomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.
|
| Absorption |
Bacitracin에 대한 Absorption 정보
Absorption of bacitracin following intramuscular injection is rapid and complete. Absorption from the gastrointestinal tract following oral administration is not appreciable. Absorption following topical application is negligible.
zinc에 대한 Absorption 정보
Not Available
Neomycin에 대한 Absorption 정보
Poorly absorbed from the normal gastrointestinal tract. Although only approximately 3% of neomycin is absorbed through intact intestinal mucosa, significant amounts may be absorbed through ulcerated or denuded mucosa or if inflammation is present.
|
| Pharmacokinetics |
Neomycin Sulfate의 약물동력학자료
- 흡수 : 경구, 경피 : 흡수되는 양이 미미하다. (3%)
- 분포 : 분포용적 : 0.36 L/kg
- 대사 : 소량이 간에서 대사된다.
- 반감기 : 3 시간 (나이와 신기능에 의존)
- 혈중최고농도 도달시간 :
- 경구 : 1-4 시간
- 근육주사 : 2 시간 이내
- 소실 :
- 주사제 : 신배설 (30-50%가 미변화체로 배설)
- 경구 : 97%가 미변화체로 변배설
Bacitracin zinc의 약물동력학자료
- 작용지속시간 : 6-8시간
- 흡수 :
- 외용 : 점막, 정상 피부, 손상된 피부로부터 거의 흡수되지 않는다.
- IM : 빠르게 흡수된다.
- 방광 관주 : 거의 흡수되지 않는다.
- 복막 세척, 종격동 세척 : 흡수된다.
- 분포 : 뇌수막염시에도 뇌척수액으로의 분포는 미미하다.
- 단백결합 : 혈중 단백에 거의 결합하지 않는다.
- 혈중최고농도 도달시간 : IM : 1-2시간
- 소실 : 24시간 이내에 10-40%가 천천히 신배설
Polymyxin B Sulfate의 약물동력학자료
- 흡수 :
- 복막에서 잘 흡수된다.
- 위장관(신생아 제외), 점막, 피부에서는 잘 흡수되지 않는다.
- 분포 :
- 반감기 : 4.5-6 시간, 신기능 저하시 연장된다.
- 혈중최고농도 도달시간 : IM : 2시간 이내
- 소실 : 사구체 여과를 통해 60% 이상이 미변화체로 신배설된다.
|
| Toxicity |
Bacitracin에 대한 Toxicity 정보
Oral, mouse: LD50 = >3750 mg/kg.
zinc에 대한 Toxicity 정보
Not Available
Neomycin에 대한 Toxicity 정보
LD50 = 200 mg/kg (rat). Because of low absorption, it is unlikely that acute overdosage would occur with oral neomycin. However, prolonged administration could result in sufficient systemic drug levels to produce neurotoxicity, ototoxicity and/or nephrotoxicity.
|
| Drug Interactions |
Bacitracin에 대한 Drug_Interactions 정보
Not Available
zinc에 대한 Drug_Interactions 정보
Not Available
Neomycin에 대한 Drug_Interactions 정보
Not Available
|
CYP450
Drug Interaction |
[CYP450 Table직접조회]
|
| Drug Target |
[Drug Target]
|
| Description |
Bacitracin에 대한 Description 정보
Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Its unique name derives from the fact that the bacillus producing it was first isolated in 1943 from a knee scrape from a girl named Margaret Tracy. As a toxic and difficult-to-use antibiotic, bacitracin doesn't work well orally. However, it is very effective topically.Bacitracin is synthesised via the so-called nonribosomal peptide synthetases (NRPSs), which means that ribosomes are not involved in its synthesis.
zinc에 대한 Description 정보
A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with anemia, short stature, hypogonadism, impaired wound healing, and geophagia. It is known by the symbol Zn.
Neomycin에 대한 Description 정보
A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)
|
| Dosage Form |
Bacitracin에 대한 Dosage_Form 정보
Ointment TopicalPowder, for solution Intramuscular
zinc에 대한 Dosage_Form 정보
Aerosol OralCapsule OralCream TopicalDressing TopicalLiquid OralLiquid SublingualLiquid TopicalLotion TopicalLozenge OralOintment RectalOintment TopicalPaste TopicalPowder OralPowder TopicalSolution IntravenousSolution / drops OralSuppository RectalTablet OralTablet, extended release Oral
Neomycin에 대한 Dosage_Form 정보
Dressing TopicalOintment OphthalmicSolution / drops Ophthalmic
|
| Drug Category |
Bacitracin에 대한 Drug_Category 정보
Anti-Bacterial AgentsAnti-Infective Agents, Local
zinc에 대한 Drug_Category 정보
Trace Elements
Neomycin에 대한 Drug_Category 정보
Anti-Bacterial AgentsAntibiotics
|
| Smiles String Canonical |
Bacitracin에 대한 Smiles_String_canonical 정보
CCC(C)C(N)C1=NCC(S1)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)CC)C(=O)NC1CCCCNC(=O)C(CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(NC(=O)C(CCCN)NC1=O)C(C)CC
zinc에 대한 Smiles_String_canonical 정보
[Zn]
Neomycin에 대한 Smiles_String_canonical 정보
NCC1OC(OC2C(N)CC(N)C(O)C2OC2OC(CO)C(OC3OC(CN)C(O)C(O)C3N)C2O)C(N)C(O)C1O
|
| Smiles String Isomeric |
Bacitracin에 대한 Smiles_String_isomeric 정보
CC[C@@H](C)[C@H](N)C1=NC[C@@H](S1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@H](C)CC
zinc에 대한 Smiles_String_isomeric 정보
[Zn]
Neomycin에 대한 Smiles_String_isomeric 정보
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O[C@H]3O[C@@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
|
| InChI Identifier |
Bacitracin에 대한 InChI_Identifier 정보
InChI=1/C66H103N17O16S/c1-9-35(6)52(69)66-72-32-48(100-66)63(97)80-43(26-34(4)5)59(93)75-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)76-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-73-39)77-60(94)44(27-38-18-13-12-14-19-38)81-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)74-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,73)(H,71,89)(H,74,90)(H,75,93)(H,76,98)(H,77,94)(H,78,96)(H,79,95)(H,80,97)(H,81,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35?,36?,37?,40-,41+,42+,43-,44+,45-,46-,47+,48?,52-,53-,54-/m0/s1/f/h71,73-83,85,87H,68H2
zinc에 대한 InChI_Identifier 정보
InChI=1/Zn
Neomycin에 대한 InChI_Identifier 정보
InChI=1/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
|
| Chemical IUPAC Name |
Bacitracin에 대한 Chemical_IUPAC_Name 정보
(4R)-4-[[(2S)-2-[[2-[(1S)-1-amino-2-methylbutyl]4,5-dihydro-1,3-thiazole-5-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(3S,6R,9S,12R,15S,18R,21S)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-15-butan-2-yl-6-(carboxymethyl)-9-(3H-imidazol-4-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-12-(phenylmethyl)-1,4,7,10,13,16,19-heptazacyclopentacos-21-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
zinc에 대한 Chemical_IUPAC_Name 정보
zinc
Neomycin에 대한 Chemical_IUPAC_Name 정보
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
|
| Drug-Induced Toxicity Related Proteins |
NEOMYCIN 의 Drug-Induced Toxicity Related Protein정보
Replated Protein:NMDA receptor-regulated protein
Drug:neomycin
Toxicity:excitotoxic activation.
[바로가기]
|
|
전문/일반
